Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17- demethoxygeldanamycin [17-AAG]) in patients with solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 5, 2013, Pages 1345-1355

  Saif, M W ^a   Erlichman, C ^b   Dragovich, T ^c   Mendelson, D ^d   Toft, D ^b   Burrows, F ^e,f   Storgard, C ^e,g   Von Hoff, D ^h  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Pinnacle Oncology Hematology   (United States)

^e BIOGEN   (United States)

^f Aarden Pharmaceuticals   (United States)

^g Ardea Biosciences Inc   (United States)

^h TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

17 Allylaminogeldanamycin; Heat shock protein 70; Heat shock protein 90; Phase 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 70; OIL; SOMATOMEDIN BINDING PROTEIN 2; TANESPIMYCIN; WATER;

ABDOMINAL PAIN; ACUTE HEPATITIS; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPOCALCEMIA; HYPOXIA; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC ENCEPHALOPATHY; MULTICENTER STUDY; NANOEMULSION; NAUSEA; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN SYNTHESIS INHIBITION; SHOCK; SIDE EFFECT; SOLID TUMOR; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZOQUINONES; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMULSIONS; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INFUSIONS, INTRAVENOUS; LACTAMS, MACROCYCLIC; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NANOPARTICLES; NEOPLASMS; RECEPTOR, ERBB-2;

EID: 84877925574     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2134-9     Document Type: Article

References (45)

1. Karapanagiotou EM, Syrigos K, Saif MW (2009) Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs 18(2):161-174
2. Young JC, Moarefi I, Hartl FU (2001) Hsp90: a specialized but essential protein-folding tool. J Cell Biol 154(2):267-273
3. Sausville EA (2001) Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 7:2155-2158
4. Ferrarini M et al (1992) Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 51:613-619
5. Schneider C et al (1996) Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci 93:14536-14541
6. Maloney A, Workman P (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2(1):3-24
7. Takimoto CH, Diggikar S (2002) Heat shock protein and proteasome targeting agents. Hematol Oncol Clin N Am 16:1269-1285
8. Banerji U, Judson I, Workman P (2003) The clinical applications of heat shock protein inhibitors in cancer present and future. Curr Cancer Drug Targets 3:385-390
9. Supko JG et al (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305-315
10. Kamal A et al (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407
11. Page J et al (1997) Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats. Proc Am Assoc Cancer Res 38
12. Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharamcol 42:273-279
13. Kelland LR et al (1999) DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940-1949
14. Neckers L, Ivy SP (2003) Heat shock protein 90. Curr Opin Oncol 15:419-424
15. Zhang H, Burrows F (2004) Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82:488-499
16. Banerji U et al (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152-4161
17. Goetz MP et al (2005) Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087
18. Grem JL et al (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885-1893
19. Ramanathan RK et al (2005) Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11:3385-3391
20. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm
21. Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205-216
22. Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren K, Burrows F (2006) Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 5(5):1256-1264
23. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3
24. Chiosis G et al (2006) Hsp90 inhibitors - a chronicle from geldanamycin to today's agents. Curr Opin Investig Drugs 6:534-541
25. Solit DB, Ivy SP, Kopil C et al (2007) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13(6):1775-1782
26. Roden DM (2004) Drug-induced prolongation of the QT interval. NEJM 350:1013-1022
27. Veerareddy PR, Vobalaboina V (2004) Lipid-based formulations of amphotericin B. Drugs Today (Barc) 40:133-145
28. Zamboni WC, Gervais AC, Egorin MJ et al (2004) Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 53:329-336
29. Allen TM, Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1068:133-141
30. Newman MS, Colbern GT, Working PK et al (1999) Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1-7
31. Working PK, Newman MS, Stuart Y et al (1994) Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in STEALTH liposomes. Liposome Res 46:667-687
32. Ewer MS, Martin FJ, Henderson C et al (2004) Cardiac safety of liposomal anthracyclines. Semin Oncol 31(suppl 13):161-181
33. Northfel DW (1994) STEALTH liposomal doxorubicin (SLD) delivers more DOX to AIDS-Kaposi's sarcoma lesions than to normal skin. Proc Am Soc Clin Oncol 13:51
34. Rose PG (2005) Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10:205-214
35. Cattel L, Ceruti M, Dosio F (2004) From conventional to stealth liposomes: a new frontier in cancer chemotherapy. J Chemother 16(suppl 4):94-97
36. Vail DM, Amantea MA, Colbern GT et al (2004) Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 31(suppl 13):16-35
37. Dragovich T et al (2005) Phase 1 study of CNF1010 (lipid formulation of 17- (allylamino)-17-demethoxygeldanamycin: 17-AAG). Clin Can Res 11:9117s
38. Ficker E, Denis AT, Wang L, Brown AM (2003) Role of the cytosolic chaperones Hsp70 and Hsp90 I maturation of the cardiac potassium channel hERG. Circ Res 92:e87-e100
39. Bhat RV, Engber TM, Zhu Y, Miller MS, Contreras PC (1997) Identification of insulin-like growth factor binding protein-2 as a biochemical surrogate marker for the in vivo effects of recombinant human insulin-like growth factor-1 in mice. J Pharmacol Exp Ther 281:522-530
40. Sandri MT, Johansson H, Colleoni M et al (2004) Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res 24:1261-1266
41. Maxwell P, van den Berg HW (1999) Changes in the secretion of insulin-like growth factor binding proteins -2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines. Cancer Lett 139:121-127
42. Chatterjee S, Park ES, Soloff MS (2004) Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Int J Urol 11:876-884
43. Hayes DF, Yamauchi H, Broadwater G et al (2001) Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: cancer and Leukemia Group B Study 8662. Clin Cancer Res 7:2703-2711
44. Hunter-Lavin C, Davies EL, Bacelar MM et al (2004) Hsp70 release from peripheral blood mononuclear cells. Biochem Biophys Res Commun 324:511-517
45. Zhong L, Peng X, Hidalgo GE et al (2003) Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detect Prev 27:285-290